Formulation and aseptic fill–finish successfully completed for Aramis Biotechnologies’ phase 1/2 clinical studies. MONTRÉAL and QUÉBEC CITY – Aramis Biotechnologies Inc., a Canadian company pioneering and a global leader in plant‑based… Read More
BURLINGTON, N.C. – Labcorp, a global leader of innovative and comprehensive laboratory services, announced the signing of a new multi‑year partnership agreement with SOMOS, one of New York’s largest Independent Practice… Read More
VANCOUVER, BC, – WAT Medical is proud to announce the publication of a landmark randomized clinical trial in JAMA Surgery, one of the world’s most reputable and high-impact surgical journals…. Read More
The draft recommendation for Kisqali® (ribociclib tablets) from Canada’s Drug Agency (CDA-AMC) supports public reimbursement for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II-III early breast cancer… Read More
Allschwil, CH – Idorsia Ltd. announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker and renal findings from the… Read More
